ArticleCurrent oncology (Toronto, Ont.)2024

Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.

Caner Acar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.